Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Cyclospora parasite illnesses have affected 28 NC counties, sickened more than 200 people
Recommended
UNC has a new chancellor. Why interim Lee Roberts got the permanent job.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.31
+3.98 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
38
39
Next >
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support.
Via
Benzinga
FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
May 20, 2022
The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.
Via
Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
May 19, 2022
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses?
Via
Investor's Business Daily
Gilead Stock Earns Rating Upgrade After Quick Turnaround
May 19, 2022
A Relative Strength Rating upgrade for Gilead stock shows improving technical performance. Will it continue?
Via
Investor's Business Daily
How Regeneron Pharmaceuticals Beat Quarterly Projections Without Leaning On Covid
May 04, 2022
Excluding the company's Covid antibody, sales surged 25% and still topped forecasts.
Via
Investor's Business Daily
Here's Why This Analyst Cut Price Target On Regeneron
May 02, 2022
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Regeneron Pharmaceuticals Earnings Perspective: Return On Capital Employed
May 16, 2022
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q1 earnings of $973.50 million, an increase from Q4 of 56.33%. Sales dropped to $2.96 billion, a 40.13% decrease between...
Via
Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
May 16, 2022
Now that all major biopharmaceutical earnings are in, we can review the financial metrics and see if our portfolio needs re-balancing.
Via
Talk Markets
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now
May 13, 2022
The race is on in eczema treatment as the biggest name faces new rivals.
Via
Investor's Business Daily
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
May 11, 2022
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.
Via
Investor's Business Daily
Stock Market Jumps, Then Dives After Fed Rate Hikes As Treasury Yields Soar: Weekly Review
May 06, 2022
Lithium plays jump on earnings, but Nasdaq at lowest level since 2020.
Via
Investor's Business Daily
$1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much
May 04, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.55% on an annualized basis producing an average annual return of 19.7%. Currently, Regeneron...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Regeneron Pharmaceuticals: Q1 Earnings Insights
May 04, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Preview: Regeneron Pharmaceuticals
May 03, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
May 02, 2022
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
Looking Into Regeneron Pharmaceuticals Inc's Recent Short Interest
April 25, 2022
Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) short percent of float has risen 6.48% since its last report. The company recently reported that it has 2.39 million shares sold...
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
If You Invested $100 In Regeneron Pharmaceuticals 10 Years Ago, Here's How Much You Would Have Today
April 21, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.58% on an annualized basis producing an average annual return of 18.92%. Currently, Regeneron...
Via
Benzinga
Why Is Checkmate Pharmaceuticals (CMPI) Stock Up 300% Today?
April 19, 2022
Checkmate Pharmaceuticals (CMPI) stock is rocketing higher on Tuesday following news that Regeneron Pharmaceuticals (REGN) is acquiring it.
Via
InvestorPlace
54 Biggest Movers From Yesterday
April 20, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
April 19, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $...
Via
Benzinga
The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu
April 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Checkmate Pharma Shares Skyrocket Over 300% On Regeneron $250M Acquisition Deal
April 19, 2022
Via
Benzinga
Why Checkmate Pharmaceuticals Shares Are Skyrocketing
April 19, 2022
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) shares are trading higher by 328.40% to $10.41 during Tuesday's pre-market session after Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a deal to...
Via
Benzinga
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
April 17, 2022
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...
Via
Benzinga
NASDAQ: REGN Shareholder Notice: Investigation over Possible Securities Laws Violations by Regeneron Pharmaceuticals, Inc.
April 15, 2022
San Diego, CA -- (SBWIRE) -- 04/15/2022 -- Regeneron Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
April 14, 2022
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.
Via
Investor's Business Daily
< Previous
1
2
...
23
24
25
26
27
28
29
30
31
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.